

2027
USEF GUIDELINES & RULES FOR
**DRUGS AND
MEDICATIONS**

800.633.2472

EFFECTIVE December 1, 2026





Online USEF
Medication
Report Form

A commitment to the health, welfare and safety of the equine athlete is the common thread that binds all equestrian sport. The USEF Equine Drugs and Medications Program is driven by this commitment.

The USEF recognizes that Horses under its jurisdiction might require legitimate, therapeutic treatment near the time of competition. The Equine Drugs and Medications Rules addresses these circumstances.

This booklet is a reference tool. The information in this booklet is current at the time of printing but is subject to change at any time. The Federation systematically refines existing drug tests to make them more sensitive, and it develops new tests. Improved testing procedures are routinely implemented at any time without prior notice. Therefore, the time guidelines contained herein may become obsolete as new and more sensitive procedures are implemented. Reliance upon these guidelines is not a defense to a charge of a rule violation in the event of a positive test. Should you have any questions, please reach out to our office: 800.633.2472 or medequestrian@usef.org

Please direct all inquiries to:

United States Equestrian Federation®, Inc.

Equine Drugs and Medications Program

Phone 800.633.2472

Email: medequestrian@usef.org



For FEI Prohibited Substances go to:
inside.fei.org/fei/cleansport/ad-h/prohibited-list

UPDATES

CETIRIZINE (Zyrtec®) RECLASSIFIED AS PERMITTED

EFFECTIVE 7/27/26

The Federation has reclassified cetirizine, commonly known by the trade name Zyrtec®, from a prohibited substance to a permitted substance. This change recognizes cetirizine's role as a second-generation antihistamine that may be used in equine practice to address certain hypersensitivity reactions.

Members should note that hydroxyzine, a parent drug of cetirizine and a first-generation antihistamine, remains prohibited. Administration of hydroxyzine may result in the presence of both hydroxyzine and cetirizine in a horse's blood or urine sample; therefore, this reclassification of cetirizine does not alter the prohibited status of hydroxyzine.

Although cetirizine is not FDA-approved for use in horses, it may be administered extra label under AMDUCA, the Animal Medicinal Drug Use Clarification Act, when used on the lawful order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship. Cetirizine has been shown to have favorable pharmacokinetic and pharmacodynamic properties in horses and may be useful in treating hypersensitivity-related conditions.

METHOCARBAMOL ADMINISTRATION RECOMMENDATION UPDATED

EFFECTIVE 7/27/26

The Federation has changed the current methocarbamol administration recommendation to a 24-hour withdrawal when any other medication or supplement has been administered within the 24 hours prior to competing.

This recommendation follows the Veterinary Committee's discussion regarding the increase in methocarbamol overages and concerns raised by members about a potential relationship between concurrent use of gastric medications/supplements and this medication. The updated recommendation is offered out of an abundance of caution and is intended to provide clearer guidance to competitors, trainers, owners, and veterinarians when methocarbamol is used in proximity to other administered products.

USEF VACCINATION RULE

EFFECTIVE 12/1/26

As of December 1, 2026, GR845, the Equine Vaccination Rule, requires that all mandatory vaccinations be valid for the duration of the time the horse is on competition grounds.

The update to this rule is to ensure vaccinations protect the horse for the duration of the event as vaccination during competition is not in the best interest of competition horse health. Administering a vaccine after arrival does not meaningfully protect the horse from exposures occurring at that competition. Furthermore, local soreness, swelling, fever, lethargy, or reduced appetite can occur after vaccination which may compromise horse health or competitive performance. Fevers on the competition grounds require reporting, investigating and potential isolation of the horse (GR873). Thus, for best protection of horse

health and an appropriate vaccination response, vaccination should be administered to a healthy horse in its home environment.

USEF MICROCHIP RULE

EFFECTIVE 12/1/26

For the purpose of safeguarding the health of equine athletes, the United States Equestrian Federation Board of Directors approved a microchipping rule to ensure the immediate onsite verification of horses. Properly placed microchips are a safe, tamper proof form of individual identification. This is vital, especially during times of disease outbreaks or natural disasters.

As of December 1, 2026, every horse entered in a USEF-licensed or endorsed competition, regardless of breed, discipline, or rating/level will be required to have a 15-digit ISO Compliant microchip implanted in the left nuchal ligament of the horse.

The USEF strongly supports the use of a biothermal ISO Compliant microchip in the left nuchal ligament as an effective means of health monitoring of our equine athletes. It is recommended that a veterinarian perform or supervise the microchipping process to ensure the safety and health of the horse. Additionally, some state laws require a veterinarian to perform microchip implantation.

If your horse already has a microchip the USEF does not recommend the implantation of second microchip unless, the chip is no longer able to be read or the chip is not an ISO compliant chip. The only time a second microchip should be considered is if a temperature sensing ISO compliant microchip is being implanted.

If you have specific questions about recording your horse's microchip, please email horseservices@usef.org. You can also go to your USEF Member Dashboard to report a microchip for your horse.

During a USEF competition the microchip may be scanned by:

- Competition staff, USEF representatives, USEF drug testing personnel, or USEF licensed officials to confirm the identity of the horse;
- Competition management for identification or recording of show results; or
- State or federal animal health officials investigating a disease outbreak to identify exposed horses; or
- Groom, trainer, or owner to monitor the health of the individual horse through the temperature sensing microchip.

For additional microchip resources or information on the USEF Microchip Rule visit the USEF Microchipping webpage. (usef.org/learn/equine-health/equine-microchipping)

GUIDELINES REGARDING THE 2027 USEF EQUINE DRUGS AND MEDICATIONS RULE

THIS INFORMATION, IF HEEDED, WILL MINIMIZE THE CHANCES OF POSITIVES FOR PROHIBITED SUBSTANCES; HOWEVER, ALL TRAINERS, OWNERS, AND EXHIBITORS ARE CAUTIONED THAT THE FOREGOING ARE ONLY GENERAL GUIDELINES, AND IT IS THE TRAINER'S RESPONSIBILITY TO SEE TO IT THAT CONDITIONS PREVAIL FOR FULL COMPLIANCE WITH ALL USEF RULES.

Introduction

The following guidelines include advice about understanding the USEF Equine Drugs and Medications Rules and applying them in practical situations. Their purpose is to help accommodate legitimate therapy in compliance with the requirements of the rules. THESE ARE ONLY GUIDELINES. It is important to consult a licensed veterinarian in determining whether the substance is required for the welfare of the Horse and when determining the dosage under the USEF Equine Drugs and Medication Rules.

Caution Against the Use of Supplements

TRAINERS, OWNERS, EXHIBITORS, AND THEIR VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, POWDERS AND PRODUCTS OF ANY KIND, INCLUDING THOSE USED TOPICALLY.

Persons administering an herbal or natural product to a Horse to affect its performance might be comforted by claims that the plant origin of its ingredients mean it is permitted by the rules and/or undetectable by drug tests. This can be misleading.

The use of herbal and natural products in a Horse might result in a positive drug test, i.e., a finding of a prohibited substance, contrary to claims by those who manufacture and/or market such products for profit. The plant origin of any ingredient does not preclude its containing a pharmacologically potent and readily detectable prohibited substance, e.g., cocaine, heroin and marijuana all come from plants.

Although the use of some of these products may not have resulted in positive drug tests in the past, this may change as the testing laboratory incorporates new methods into its battery of screening tests, a deliberate and ongoing process.

For the above reasons, the Federation cautions against the use of herbal and natural products. The ingredients and properties of products classified as prohibited include, but are not limited to, valerian, kava kava, passionflower, skullcap, chamomile, vervain, leopard's bane, night shade, capsaicin, comfrey, devil's claw, hops, laurel, lavender, red poppy and rauwolfia.

"Approved" Or "Endorsed" Products

USEF does not approve, endorse, or sanction herbal, natural or medicinal products of any kind. Trainers, owners and exhibitors are advised to disregard any such representations, statements or testimonials made by the manufacturer. Any individual who becomes aware of a product, the label of which contains a statement that it is "USEF Approved" or "USEF Endorsed," etc., should forward a copy of the label to the office of the Equine Drugs and Medications Program.

To determine whether the ingredients in a supplement are

permissible, please email medequestrian@usef.org with:

- The rules under which the horse will be competing, and
- A complete list of the product's ingredients.

A photo of the product label, a link to the manufacturer's website showing the ingredients, or the ingredient list included directly in the email are all acceptable. Please note that AI-generated ingredient summaries will not be accepted and should not be relied upon.

Manufacturers may change product formulations at any time. Any review conducted by the USEF Equine Drugs and Medications Program applies only to the ingredients disclosed at the time of review.

Even if the label does not contain any prohibited substances, the use of the supplement is at your own risk, particularly those that claim to calm horses. Supplements are not regulated by the FDA and as a result, there is no guarantee as to the safety, efficacy, quality, or even consistency of the contents.

The Veterinarian's Responsibilities

When dealing with illness or injury in a Horse competing at a USEF recognized show or event, the veterinarian should prescribe or administer whatever is indicated for therapeutic purposes. When prescribing or administering a substance prohibited or restricted by the rules, the veterinarian should advise the exhibitor, trainer, and owner how to comply with USEF Rules. However, if the veterinarian (1) fails to give them proper advice, or (2) gives them improper advice about compliance with the rules, or (3) if the trainer, owner, or exhibitor fails to heed the proper advice of the veterinarian, then the trainer and owner may be subject to penalties under Federation Rules.

No veterinarian should be party to the administration of a drug or medication to a Horse for the non-therapeutic purpose of affecting its performance. This is unethical, and it encourages unethical conduct among trainers, owners, and exhibitors. Such conduct is contrary to USEF Rules, and undermines the fairness of competition.

The Trainer's Responsibilities

Under USEF Rules, the trainer is held responsible and accountable for the condition of the Horse and for compliance with the rules. The trainer is defined as any adult or adults who has or shares the responsibility for the care, training, custody, condition or performance of the Horse. This could be one person or several individuals. Trainers, in the absence of substantial evidence to the contrary, are responsible and accountable under the penalty provisions of these rules, regardless of whether they have signed an entry blank. They are also responsible for guarding each Horse at, and sufficiently prior to, a recognized competition. Such as to prevent the administration by anyone of or its exposure to any prohibited substance, and to know all the provisions of this rule and all other rules and regulations of the Federation and the penalty provisions of said rules.

For the purposes of this rule, substantial evidence means affirmative evidence of such a clear and definite nature as to establish that the trainer or any employee or agent of the trainer was, in fact, not responsible or accountable for the condition of the Horse.

The Requirement to Submit, Observe, Cooperate, and Assist

GR402 requires trainers, owners, and their representatives to submit their Horses to the collection of blood, urine and hair samples, at the

discretion of the testing veterinarian appointed by USEF. The animal is to be left in the charge of the testing personnel until all sample collections are completed, or until, in the exclusive discretion of the testing personnel, the animal is released.

In accordance with GR402, trainers are urged to accompany the testing personnel and the animal during the time that samples are collected, labeled, and sealed, and to serve as witness to these procedures. In the event he or she is unwilling or unable to do so, the trainer is urged to appoint an agent to serve as witness to these procedures. Failure to witness these procedures, and/or failure to appoint an agent to do so, precludes a trainer from subsequently challenging the identity of the Horse from which samples were collected, or the procedures employed in collecting, labeling, or sealing the samples.

GR403 requires trainers, owners, and their agents to cooperate with the testing personnel, to take the Horse immediately to the location selected by the testing personnel for sample collections, to present the animal for sample collections, to cooperate in the prompt procurement of samples with no unnecessary delays, and to exhibit polite attitude and actions to the testing personnel at all times. It is a violation for any individual to attempt to intimidate or interfere with testing personnel.

Failure to comply with all of the requirements of GR402 and 403 is a potentially serious violation of the rules that can result in the issuance of charges of a rule violation by the Federation. Those found to have violated these rules can be subject to suspensions, fines, and return of winnings, at the discretion of the Federation's Hearing Committee.

Different Rules for Different Groups

GR410-412 applies to most breeds and disciplines that compete under USEF Rules subject to the Therapeutic Substance Provisions.

GR409 contains the Prohibited Substance Provisions and applies to all FEI recognized disciplines. The Endurance Discipline is subject to the Prohibited Substance Provisions (GR409).

FEI recognized events are subject to the FEI Veterinary Regulations and the FEI Equine Anti-Doping and Controlled Medication Regulations. The FEI maintains a Prohibited Substance Rule, which includes reporting requirements for the treatment of illness and injury. See fei.org for more information on FEI Equine Anti-Doping and Controlled Medication Rules.

Conditions for Therapeutic Administrations of Prohibited Substances

Under certain conditions, some prohibited substances may be used in compliance with USEF Equine Drugs and Medications Rules for therapeutic reasons. The complete process and conditions are provided in GR411. See EXAMPLES OF COMMON PROHIBITED SUBSTANCES UNDER USEF RULES herein.

If a Horse is administered a product containing prohibited substances, the animal may return to competition if the following requirements are met:

1. The product containing the prohibited substance must be used for a legitimate therapeutic purpose only. The rule includes a provision for the use of a prohibited substance for the diagnosis or treatment of illness or injury only. If a prohibited substance is administered

for any other purpose, e.g., clipping, shipping, training, the animal must be kept out of competition until the prohibited substance is no longer detectable in the animal's blood or urine sample. Depending upon the prohibited substance this can be a long time (see examples herein under HOW LONG DRUGS REMAIN DETECTABLE).

2. The product containing a prohibited substance must be administered by or at the direction of a veterinarian.
3. After a Horse is administered a product containing a prohibited substance for a legitimate therapeutic purpose, **the animal must be withdrawn from competition for at least 24 hours**. This is a uniform requirement for all therapeutic prohibited substances and there are no exceptions.
4. A Medication Report Form (MRF) must be filed documenting the therapeutic use of a prohibited substance. This must be done before the Horse competes.

All MRFs must be filed online. A link to the online form can be found at competitions.usef.org/medicationreportform/usef. If an online form cannot be submitted due to lack of internet or phone service, a paper form may be submitted. This option must only be used when submitting the online form is impossible. When submitting a paper form, it must be done within one hour after administration.

If the requirements of GR411 are fully satisfied, the Federation will consider any MRFs and all other relevant evidence in determining whether a rule violation occurred in the event of a positive test result.

Guidelines for the Therapeutic Use of Dexamethasone and Other Corticosteroids

USEF Rules provide for the use of corticosteroids such as dexamethasone in Horses only for a therapeutic purpose, i.e., for the treatment of existing inflammatory conditions related to illness or injury. The rules do not permit the use of corticosteroids for a non-therapeutic purpose, i.e., to affect the mood or enhance the performance of the Horse.

The rules establish a quantitative restriction for dexamethasone, i.e., a maximum permitted plasma concentration (fluid portion in blood).

In order to help trainers, owners, and their veterinarians achieve compliance with this rule in connection with the therapeutic use of dexamethasone, it should be administered in accordance with the guidelines herein. Whenever dexamethasone is administered, the dose should be accurately calculated according to the actual weight of the animal. Due to the 12-Hour Rule prohibiting injections from being administered within the 12 hours prior to competing, a plasma level of 0.5 nanograms per milliliter at the time of competition has been determined to be the maximum allowable plasma concentration when dexamethasone is administered.

Alternative Number 1

Dexamethasone administration IV or IM at 12 or more hours prior to competing

Each 24 hours, not more than 1.0 milligrams of dexamethasone injectable solution per 100 pounds of body weight should be administered intravenously or intramuscularly. For a 1000 pound animal, the maximum daily intravenous or intramuscular dose of dexamethasone injectable solution is 10.0 milligrams, which equals 2.5

milliliters of the injectable solution (4.0 milligrams per milliliter). No part of this dose should be administered during the 12 hours prior to competing. Dexamethasone should not be administered for more than five successive days.

Alternative Number 2

Dexamethasone administration IV at 6 or more hours prior to competing by a licensed veterinarian for the treatment of hives (urticaria)

IMPORTANT: This alternative dose for dexamethasone can only be administered by a licensed veterinarian for the treatment of hives (urticaria). A Medication Report Form must be filed consistent with GR411. The filing of a Medication Report Form is required to document compliance with the 12-Hour Rule prohibiting injections in the 12-hour period prior to competing.

Each 24 hours, not more than 0.5 milligrams of dexamethasone injectable solution per 100 pounds of body weight should be administered intravenously, preferably less. For a 1000-pound animal, the maximum daily intravenous dose of dexamethasone injectable solution is 5.0 milligrams, which equals 1.25 milliliters of the injectable solution (4.0 milligrams per milliliter). No additional dose should be administered during the 12 hours prior to competing. Dexamethasone should not be administered for more than five successive days.

Alternative Number 3

Dexamethasone administration orally at 12 or MORE hours prior to competing.

Each 24 hours, not more than 1.0 milligrams of dexamethasone powder per 100 pounds of body weight should be administered orally, preferably less. For a 1000-pound animal, the maximum daily oral dose of dexamethasone powder is 10.0 milligrams, which equals one packet of dexamethasone powder (10.0 milligrams per packet). No part of this dose should be administered during the 12 hours prior to competing. Any medicated feed should be either consumed or removed at least 12 hours prior to competing. Dexamethasone should not be administered for more than five successive days.

Additional Considerations

Corticosteroids other than dexamethasone, e.g., prednisone, prednisolone, Solu-Delta-Cortef®, triamcinolone acetone, betamethasone, methylprednisolone (Depo-Medrol®) and others, are classified as prohibited substances, and use of these drugs is subject to the requirements of GR411. This means these substances are to be used only for a therapeutic purpose, i.e., for the treatment of existing inflammatory conditions related to illness or injury; they are to be administered at a time not closer than 24 hours prior to competing; and a MRF must be filed under USEF rules in connection with any administration performed by any route during the 7 days prior to competing. When using the corticosteroid methylprednisolone (Depo-Medrol®), the recommendation is to file a Medication Report Form if competing within 14 days of administration.

When using the corticosteroid isoflupredone (Predef2X®) in injecting the sacro-iliac (SI) joint, the recommendation is to file a MRF if competing within 28 days of administration.

Trainers, owners, and their veterinarians are cautioned against the use of dexamethasone isonicotinate injectable solution, because

administration studies have shown it is not eliminated from the plasma as quickly as dexamethasone injectable solution. Therefore, the use of dexamethasone isonicotinate injectable might result in an inadvertent overage, i.e., a plasma concentration of dexamethasone in excess of the maximum permitted plasma concentration of 0.5 nanograms per milliliter at the time of competition.

Whenever dexamethasone injectable solution or dexamethasone oral powder is administered in a manner that might cause the plasma concentration to exceed the maximum permitted by the rule, the trainer and owner must withdraw the animal from competition for a sufficient amount of time such that the plasma concentration of dexamethasone returns to acceptable limits prior to competition.

Products or preparations that contain dexamethasone or another corticosteroid as an active ingredient (e.g. a Naquasone® bolus contains 5.0 milligrams of dexamethasone), should be used in accordance with the guidelines listed, taking into account the actual weight of the animal. Some products or preparations containing dexamethasone may also contain a diuretic (e.g. hydrochlorothiazide or chlorothiazide) which is considered a prohibited substance and a Medication Report Form must be filed to document compliance with GR411 when using these products.

Guidelines for the Therapeutic Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

GR410 restricts the use in Horses of not more than one nonsteroidal anti-inflammatory drug (NSAID) at a time (of those permitted to be used), imposes quantitative restrictions on those permitted, and forbids the use of any other NSAID. The information in this section will help owners, trainers, and their veterinarians stay in compliance with these rules, as they treat their Horses with NSAIDs.

NSAIDs are to be administered to a Horse only for a therapeutic purpose. The following are permitted to be used, as long as the plasma levels are below their respective quantitative restrictive levels found in GR410 (these are the generic names, not brand names): diclofenac liposomal cream, firocoxib, phenylbutazone, flunixin meglumine, ketoprofen, meclofenamic acid, and naproxen.

The NSAIDs listed above should be administered in accordance with the guidelines below, and no other NSAIDs are to be administered.

Brand name examples:

Surpass (diclofenac liposomal)

Equioxx (firocoxib)

Bute (phenylbutazone)

Banamine, Flunazine (flunixin meglumine)

Ketofen (ketoprofen)

Arquel (meclofenamic acid)

Naproxen

1. Whenever diclofenac liposomal cream is administered, not more than 73 mg should be administered, to not more than one affected site, each 12 hours (i.e., not more than 146 mg per 24 hour period). This 73 mg dose equals a 5-inch ribbon of cream not greater than ½ inch in width, which should be rubbed thoroughly into the hair over the joint or affected site using gloved hands. Administration

of diclofenac cream should be discontinued at least 12 hours prior to competing. Do not apply diclofenac cream in combination with any other topical preparations including DMSO, nitrofurazone, or liniments, and do not use on an open wound. The maximum treatment time for diclofenac cream is 10 successive days.

2. Whenever firocoxib is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 0.0455 mg per pound of body weight should be administered. For a 1000 pound animal, the maximum daily dose is 45.5 mg, which equals four markings on the dosing syringe that contains the medication and is supplied by the manufacturer. No part of a dose should be administered during the 12 hours prior to competing. Any medicated feed must be consumed and/or removed at least 12 hours prior to competing. The maximum recommended treatment time for firocoxib is 14 successive days.
3. Whenever phenylbutazone is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 2.0 milligrams per pound of body weight should be administered, preferably less. For a 1000-pound animal, the maximum daily dose is 2.0 grams, which equals two 1.0 gram tablets, or two 1.0 gram units of paste, or 10.0 cc of the injectable (200 milligrams per milliliter). Neither a total daily dose nor part of an injectable dose should be administered during the 12 hours prior to competing. In the event the phenylbutazone is administered orally, half of the maximum daily dose (1.0 grams per 1000 lbs.) can be administered each 12 hours during a five-day treatment program. The maximum recommended treatment time for phenylbutazone is five successive days.
4. Whenever flunixin meglumine is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 0.5 milligrams per pound of body weight should be administered, preferably less. For a 1000-pound animal, the maximum daily dose is 500 milligrams, which equals two 250 milligram packets of granules, or one 500 milligram packet of granules or 500 milligrams of the oral paste (available in 1500 milligram dose syringes), or 10.0 cc of the injectable (50 milligrams per milliliter). No part of a dose should be administered during the 12 hours prior to competing. Any medicated feed must be consumed and/or removed at least 12 hours prior to competing. The maximum recommended treatment time for flunixin meglumine is five successive days.
5. Whenever ketoprofen is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 1.0 milligrams per pound of body weight should be administered, preferably less. For a 1000-pound animal, the maximum daily dose is 1.0 grams, which equals 10.0 cc of the injectable (100 milligrams per milliliter). No part of a dose should be administered during the 12 hours prior to competing. The maximum recommended treatment time for ketoprofen is five successive days.
6. Whenever meclofenamic acid is administered, the dose should be accurately calculated according to the actual weight of the animal.

Each 12 hours, not more than 0.5 milligrams per pound of body weight should be administered, preferably less. For a 1000-pound animal, the maximum 12 hour dose is 0.5 grams, which equals one 500 milligram packet of granules. The maximum recommended treatment time for meclofenamic acid is five successive days.

7. Whenever naproxen is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 4.0 milligrams per pound of body weight should be administered, preferably less. For a 1000-pound animal, the maximum daily dose is 4.0 grams, which equals eight 500 milligram tablets. No part of a dose should be administered during the 12 hours prior to competing. Any medicated feed should be consumed and/or removed at least 12 hours prior to competing. The maximum recommended treatment time for naproxen is five successive days.
8. Whenever a permitted NSAID is administered, any additional permitted NSAID must not have been administered during the three (3) days prior to competing.
9. Whenever any NSAID is administered that is not permitted to be used, it should not have been administered during the seven (7) days prior to competing.
10. Whenever any NSAID is administered to a Horse in a manner that might cause the plasma concentration to exceed the quantitative restrictions of the rule (in the case of those permitted to be used), or might cause more than one NSAID to be detected in the animal's blood or urine sample, or might cause the NSAID to be detected at any concentration in the animal's blood or urine sample (in the case of those not permitted to be used), the trainer and owner must withdraw the Horse from competition, and the animal should be withheld from competition until the plasma concentration of any permitted NSAID returns to acceptable concentrations and/or until any NSAID prohibited at any concentration is no longer present in the animal's blood or urine sample.

Guidelines for the Therapeutic Use of Methocarbamol

1. Whenever methocarbamol is administered, the dose should be accurately calculated according to the actual weight of the Horse. Each 24 hours, not more than 5.0 mg per pound of body weight should be administered, preferably less. For a 1000-pound animal, the maximum dose each 24 hours is 5.0 grams, which equals ten 500 milligram tablets or 50 cc of the injectable (100 milligrams per milliliter). No dose should be administered during the 24 hours immediately following the prior dose.
2. No part of the dose should be administered during the 24 hours prior to competing when any other medication or supplement has been or will be administered during that time period. If the horse is not receiving any other medication or supplement, the recommended withdrawal time is 12 hours prior to competing. These withdrawal recommendations include consumption or removal of any medicated feed.

The maximum recommended treatment time for methocarbamol is five successive days.

In any instance methocarbamol has been administered to a Horse in a manner that might cause the plasma concentration to exceed the quantitative restriction of the rule, the trainer and owner must withdraw the Horse from competition, and the animal should be withheld from competition until the plasma concentration returns to acceptable levels.

ANABOLIC STEROIDS

Anabolic steroids are prohibited for all breeds and disciplines competing under USEF Rules. No anabolic steroid is to be administered to a Horse in the time before competition such that it, or any metabolite of it, might be present in the animal, or might be detectable in its blood or urine sample at the time of competition. This means that no anabolic steroids can be administered and/or any surgical implants must be removed sufficiently in advance of competing such that these substances are not present in the blood or urine at the time of competition (see herein HOW LONG DRUGS REMAIN DETECTABLE)

INJECTABLE SYNTHETIC PEPTIDES

Injectable synthetic peptides are prohibited under USEF Rules. Common names include, but are not limited to, BCP-157, TB500, and TB1000.

They are prohibited in competing horses because they may alter normal physiology in ways that could enhance performance, accelerate recovery, mask pain or injury, or otherwise compromise horse welfare and the integrity of competition. Many of these products intended for horses lack FDA approval and peer-reviewed scientific evidence demonstrating efficacy, safety, appropriate dosing, or predictable effects in horses. In addition, synthetic peptides may be manufactured under conditions where quality control and assurances as to contents may be lacking.

THE ADMINISTRATION OF PERGOLIDE

Pergolide has been the mainstay treatment of Equine Cushing's disease, also known as Pituitary Pars Intermedia Dysfunction (PPID), for several decades. Due to the class of drug that pergolide represents, it is a prohibited substance under FEI and USEF rules. Currently, under USEF GR411 Conditions For Therapeutic Administrations of Prohibited Substances, pergolide can be administered, but requires a 24-hour withdrawal from treatment prior to competition and represents a hardship to competitor and Horse.

Effective December 1, 2018, Horses that are granted a Therapeutic Use Exemption (TUE) for pergolide can remain on pergolide with no withdrawal of drug prior to competition and no need to file a MRF each time they compete.

What is Cushing's?

Equine Cushing's disease, also known as pituitary pars intermedia dysfunction (PPID), is probably the most common disease of geriatric Horses. Affected Horses show a variety of clinical signs, including excessive hair growth with reduced to no seasonal shedding, frequent urination and drinking, suppression of the immune system, muscle wasting, and founder.

What is pergolide?

Pergolide is the most common medication used for the treatment of Cushing's disease/PPID and is a prohibited substance under USEF Equine Drugs and Medications Rules.

What is a pergolide Therapeutic Use Exemption (TUE)?

This is an exemption for the use of pergolide in those competition Horses with documented disease.

Does this mean that pergolide is a permitted medication?

No, pergolide will continue to be a prohibited substance under USEF Equine Drugs and Medications Rules, but the TUE process will permit the continuous treatment of Cushing's disease/PPID in competition Horses documented with the disease.

Does the TUE process apply for FEI competitions?

No, pergolide is considered a prohibited substance under FEI rules and is not permitted in competition, and no exemption or form applies.

How does this differ from a Medication Report Form (MRF)?

The use of a MRF requires the withdrawal of a Horse from competition for 24 hours following the last administration of a prohibited substance. Having a TUE permits the horse to compete without having to observe a 24-hour withdrawal from pergolide or file an MRF. If a horse does not have a TUE, trainers are still able to administer Pergolide per GR411 by observing a 24-hour withdrawal and filing an MRF.

How do I apply for a TUE for pergolide?

The process can be initiated with the filing of an electronic MRF for pergolide. Just complete the online MRF and check the box, and the process will start. Once the request for consideration is received, an email will be sent with a request for more information from the treating veterinarian.

How long will a pergolide TUE be effective, and is it necessary to reapply?

A pergolide TUE will be effective for three years from the approval date. Prior to the TUE's expiration, a request can be made to extend the effective period for an additional three years.

How does this change the way my Horse with Cushing's/ PPID needs to be medicated with pergolide?

If your Horse is granted a TUE based upon documented medical tests and clinical history, there will be no need to file MRFs at each competition or to change the frequency or schedule of their pergolide treatment.

What kind of information does my veterinarian need to provide for my Horse to be granted a pergolide TUE?

The treating veterinarian should provide a history of the Horse's clinical signs and any diagnostic tests that have been completed. This information will be submitted by the veterinarian, along with any documents, including diagnostic tests and case notes, which can be uploaded as part of the application. The ideal diagnostic test for submission is a Thyrotropin Releasing Hormone (TRH) stimulation test.

How long will it take to be notified about my request for a TUE?

Once the application is complete, and all supporting information has

been submitted, the process may take between one and four weeks. Once the application is reviewed, your veterinarian may be contacted for follow up information prior to a decision.

Can a TUE be used for other treatments?

No, the use of a TUE can only be requested for pergolide at this time. The USEF recognizes the benefit of this medication in the treatment of Cushing's/PPID-affected Horses to normalize the endocrine feedback mechanisms disrupted by this disease.

**THE ADMINISTRATION OF ALTRENOGEST/
PROGESTOGEN**

The use of any progestogens in stallions and geldings while competing in USEF licensed competitions is prohibited.

Altrenogest, known as Regu-Mate® commercially, is the FDA-approved synthetic progestogen commonly administered to mares to suppress estrus and associated seasonal behaviors in competing Horses, and to aid in breeding practices with broodmares.

While alternatives exist for males (gelding), surgical removal of the ovaries is not as easily accomplished as in other species. Altrenogest provides a means to normalize mares during estrus.

Altrenogest will continue to be permitted for use in mares under Federation rules.

EXAMPLES OF COMMON PROHIBITED SUBSTANCES UNDER USEF RULES



The next two pages are examples only. This is **NOT** a comprehensive list of Prohibited Substances. Contact the USEF Drugs and Medications Office for guidance 1 800-633-2472.
Potentially Permitted with Medication Report Form (MRF) according to GR411:

acepromazine	epinephrine (adrenaline)	pramoxine (Caladryl®)
acetylpromazine	ertugliflozin	prilocaine
albuterol (Salbutamol®)	etamiphylline	procaine
aminophylline	etidocaine	procaine penicillin (penicillin G; intramuscular)
antihistamines (class of drugs)	fentanyl	promazine
apomorphine	furosemide (Lasix®)	promethazine
atropine	glycerol guaiacolate	pseudophedrine (Tri-Hist Granules®)
benzocaine (Anbesol®, Cepacol®)	glycopyrrolate	pyrilamine (Tri-Hist Granules®)
betamethasone (Celestone®, Soluspan®)	guaifenesin (Mucinex®)	romifidine (Sedivet®)
bethanechol chloride	hydrochlorothiazide (Naquasone® compounded products)	salmeterol
bupivacaine (Marcaine®)	hydroxyzine	scopolamine
buprenorphine (Bruprenex®)	ipratropium (Atrovent®)	SGLT-2 inhibitors (Ertugliflozin®, etc.)
butorphanol (Torbugesic®)	isoflupredone (Predef 2x®)	terfenadine
camphor	ketamine	tetracaine
chlorothiazide	lidocaine	theophylline
chlorpheniramine	lorazepam	tiludronate disodium (bisphosphonate; Tildren®)
Ciclesonide (Aservo® EquiHaler®)	medetomidine (Domitor®)	triamcinolone
clenbuterol (Ventipulmin®)	mepivacaine (Carbocaine® V)	acetone (Vetalog®)
clodronate disodium (bisphosphonate; Osphos®)	metformin	trichlormethiazide (formerly in Naquasone®)
codeine	methylprednisolone (DepoMedrol®)	tripelennamine
cyproheptadine	morphine	tropicamide
dantrolene (Dantrium®)	naloxone	xylazine (Rompun®, AnaSed®)
desmethylpyrilamine	nefopam	xylocaine
detomidine (Dormosedan®)	nitroglycerin	
dextromethorphan	orphenadrine citrate	
dextromoramide	oxybutynin (Ditropan®)	
diazepam (Valium®)	oxymetazoline	
diphenhydramine (Benadryl®)	passion flower	
dipyrrone (Zimeta®)	pentoxifylline	
doxapram	pergolide mesylate	
dyphylline	phenylephrine	
	phenytoin	
	piperacetazine	

Note: Some drugs in these classes are not acceptable with the MRF.

*benzodiazepines
beta blockers
corticosteroids
opiates*

No Medication Report Form (MRF) Accepted

acetaminophen	ethacrynic acid	nalmeferine
acetophenazine	ethchlorvynol	nandrolone
alfentanil	ethyl alcohol	nikethamide
Alpha-casozepine (Zylkene®)	etodolac	nitrazepam
alprazolam	etomidate	night shade
	etorphine	oxitriptan (5-HTP)
amitriptyline (Elavil®)	eugenol	oxymetazoline (Afrin®)
amphetamines (class of drugs)	fenfluramine	oxymorphone
apomorphine	fenspiride	paroxetine
arsenic	fentiazac	pentazocine
ashwaghandha	fluanisone	pentobarbital
azaperone	fluoxetine (Prozac®)	phencyclidine
barbiturates (class of drugs)	fluphenazine (Prolixin®)	phenibut
belladonna	GABA	phenobarbital
benperidol	gabapentin (Neurontin®)	phentermine
bisphosphonates (except those FDA approved for equine use)	ginger root	phenylpropanolamine
boldenone	guanabenz (Wytensin®)	piperacetazine
BPC-157	haloperidol	pirenperone
bromperidol	homotropine	prazepam
bumetanide	hydrocodone	prethcamide
buspirone	hydromorphone	procaterol
caffeine	imipramine	prochlorperazine
calendula	kava kava	procyclidine
cannabinoids including CBD (Cannabidiol) (synthetic & natural) and other cannabimimetics	ketorolac	propentofylline
capsaicin	L-theanine (a non-essential amino acid)	propiomazine
carfentanil	laurel	propionylpromazine
carisoprodol ("Soma-tabs")	leopard's bane	propoxyphene
carprofen (Rimadyl®)	levallorphan	propranolol
chloral hydrate	levorphanol	ractopamine (Paylean®)
chloralbutanol	Liquid Nitrogen	rauwolfia
chlorpromazine (Thorazine®)	lithium	red poppy
chlorprothixene	lorazepam (Ativan®)	reserpine (Serpasil®)
clozapine	LSD	risperidone
cocaine	mabuterol	sertraline
comfrey	mazindol	sodium cacodylate
cyclobenzaprine	medizine	spiperone
delta 8 THC	medroxyprogesterone acetate (MPA; Depo-Provera®)	sufentanil
devil's claw	meloxicam (Metacam®)	stanozolol (Winstrol®-V)
dextromoramide	meperidine	strychnine
dezocine	mepenzolate bromide	sumatriptan
digoxin	mephentermine	synephrine
dipremorphine	mepylcaine	terbutaline sulfate
doxepin	methadone	testosterone
droperidol	methaqualone	THC
dyphylline	methamphetamine	theobromine
ephedrine	methylodopa	thymosin-synthetic (TB500/TB1000)
epoetin alfa (Epogen®)	methylphenidate (Ritalin®)	tolmetin
erythroethanol (EPO)	metomidate	tramadol
	milnerperone	trazodone
	minoxidil	trifluoperidol
	molindone	trihexyphenidyl
	moperone	valerian
	nalbuphine	vervain
		zileuton
		zolpidem (Ambien®)

RESTRICTED MEDICATION DOSE AND TIME RECOMMENDATIONS



This chart is for quick reference only and should not be used in place of the detailed guidelines on the following pages.

MEDICATION GENERIC NAME	MEDICATION TRADE NAME	MAX DOSAGE PER POUND OF BODY WEIGHT	LATEST ADMINISTRATION HOUR PRIOR TO COMPETITION	ADMINISTRATION METHOD (single dose per 24 hours unless specified otherwise)	CLASS OF DRUG
Dexamethasone	Azium®	1.0 mg/100Lb (10 mg/1000Lb) or 0.5 mg/100Lb (5.0 mg/1000Lb) or	>12 hours >*6 hours	Oral, IV, IM *IV	Corticosteroid
Diclofenac	Surpass®	5 inch ribbon, ½ inch thick, one site	>12 hours	Topical, 2 doses each day 12 hours apart	NSAID
Firocoxib	Equioxx®	0.1 mg/kg (0.0455 mg/Lb) (45.5 mg/1000Lb)	>12 hours	Oral	NSAID
Phenylbutazone ("bute")	Butazolidin®	2.0 mg/Lb (2.0 grams/1000Lb) or 1.0 mg/Lb (1.0 grams/1000Lb)	>12 hours AM & PM feed	Oral, IV Oral, 2 doses each day, 12 hours apart	NSAID
Flunixin meglumine	Banamine®	0.5 mg/Lb (500 mg/1000Lb)	>12 hours	Oral, IV	NSAID
Ketoprofen	Ketofen®	1.0 mg/Lb (1.0 gram/1000Lb)	>12 hours	IV	NSAID
Meclofenamic acid	Arquel®	0.5 mg/Lb (500 mg/1000Lb)		Oral, 2 doses each day, 12 hours apart	NSAID
Naproxen	Naprosyn®	4.0 mg/Lb (4.0 grams/1000Lb)	>12 hours	Oral	NSAID
Methocarbamol	Robaxin®	5.0 mg/Lb (5.0 grams/1000Lb)	>12 hours alone; > 24 hours with other meds/supple- ments	Oral, IV	Muscle relaxant

* MUST BE ADMINISTERED BY A
VETERINARIAN AND A MEDICATION
REPORT FORM FILED.

PLEASE NOTE

DO NOT administer more than one permitted NSAID at a time within the 72 hours prior to the Horse entering the competition ring.

Whenever two NSAIDs are administered, one must be discontinued at least three (3) days prior to competing.

Whenever any NSAID is administered that does not appear on the permitted list (GR 410.4), it must not have been administered during the seven days prior to competing. Exception: Dipyrone is not considered a second NSAID; GR411 will apply.

Ex. Meloxicam is not an approved NSAID and must not be administered within the 7 days prior to competing.

The maximum treatment time for any of the above permitted medications is five days, with the exceptions of diclofenac and firocoxib.

The maximum treatment time for diclofenac is 10 successive days, and the maximum treatment time for firocoxib is 14 successive days.

Caution is urged when using compounded medications with varying administration routes not specified above. ONLY the above administration routes with non-compounded medications have been evaluated for the dose and time recommendations. **Injectable medications have not been evaluated for oral administration.**

HOW LONG DRUGS REMAIN DETECTABLE

The below information is applicable to most Horses. Nevertheless, reliance upon it does not guarantee compliance with the rules, since the response of individual Horses may vary. Exhibitors, owners, and trainers should consult the drug manufacturer and knowledgeable veterinarians for up-to-date information and more specific advice concerning the therapeutic use of a drug or medication for a particular Horse.

The below information is made available with the assumption that all drugs and medications are used only for a therapeutic purpose, i.e., the diagnosis and/or treatment of illness or injury, and that any dose administered is a conservative, therapeutic dose, consistent with the manufacturer's recommendations. The following guidelines are not part of the rules and will not serve as a defense to a charge of violation of the rule in the event of a positive drug test.

Depending upon the drug administration scenario, e.g., the formulation of the drug, the dose or doses administered, the frequency of administration, the route or routes of administration, the weight of the Horse, the health condition of the animal, etc., it is possible that the following substances and their metabolites (by-products) might remain detectable in the blood or urine sample of the animal for a number of days following the final administration of the substance, as follows:

Anabolic Steroids (GR411 does not apply)

<i>boldenone</i>	82 days
<i>nandrolone</i>	35 days
<i>stanozolol</i>	47 days
<i>testosterone</i>	30 days

Long-acting Tranquilizers and Psychotropics

(GR411 does not apply)

<i>long-acting tranquilizers and psychotropics, e.g., fluphenazine and reserpine</i>	90 days
<i>gabapentin</i>	14 days

Shorter-acting Tranquilizers and Sedatives

<i>shorter-acting tranquilizers and sedatives, e.g., acepromazine, detomidine, and xylazine</i>	7 days
<i>detomidine (Dormosedan®)</i>	48 hours

The 48 hour detection time is dose dependent, which means administering this drug in excess of a single intravenous dose (20 µg/kg, or 0.9 mg/100lb) can increase the potential for a positive finding. Detomidine is a sedative and the penalties for detections can involve significant fines and suspensions.

GR411 does not apply for non-therapeutic uses of this drug, and a medication report form should not be filed if used non-therapeutically more than 48 hours prior to competition.

**Please consult your veterinarian for guidance in following the above dosing recommendation.*

Other Medications

<i>Bisphosphonates, e.g., Osphos® and Tildren® ; only FDA approved for equine use</i>	28 days
<i>Procaine and procaine penicillin</i>	14 days
<i>local anesthetics other than procaine, e.g., lidocaine and mepivacaine</i>	7 days
<i>methylprednisolone</i>	14 days
<i>isoflupredone (intra-articular injection)</i>	7 days
<i>isoflupredone (sacroiliac injection)</i>	28 days
<i>corticosteroids other than methylprednisolone and isoflupredone, e.g., triamcinolone and betamethasone</i>	7 days
<i>nonsteroidal anti-inflammatory drugs, phenylbutazone and flunixin</i>	3 days
<i>antihistamines, e.g., cyproheptadine and pyrilamine</i>	7 days
<i>hydroxyzine</i>	10 days
<i>respiratory drugs, e.g., albuterol</i>	7 days
<i>medroxyprogesterone acetate (Depo-Provera®)</i>	90 days

The above information about drug detection serves two main purposes. In the context of competing under the USEF's Prohibited Substance Rule (GR 409) or under FEI Regulations (in the United States) it provides information about how long after the administration of a particular drug it is necessary to refrain from competition in order for the Horse to compete in compliance with the rules. In the context of competing under the USEF's Therapeutic Substance Rule (GR 410-412), it provides information about how long after the administration of a prohibited, therapeutic substance it is necessary to file a Medication Report Form (MRF) in order for the Horse to compete in compliance with the rule.

In the case of prohibited, non-therapeutic substances, e.g. fluphenazine and reserpine, it provides information about how long after the administration of such a drug substance it is necessary to refrain from competition in order for the drug substance to be no longer detectable in the blood or urine sample of the Horse.

The above information is applicable for Horses competing in the United States under USEF rules. It is not applicable to any animal competing outside the United States or under any alternate drug testing program.

The FEI may publish alternate detection times for some substances which are to be followed when competing under FEI rules. Please review FEI List of Detection Times at: <https://inside.fei.org/system/files/FEI%20Detection%20Times%202024.pdf>

For guidelines on any other drug or medication, call 800.633.2472

DRUG TESTING FAQ

Am I allowed to stay and watch? How can I be sure the sample was collected properly and labeled correctly?

Yes, you may stay and observe the entire process, or you may ask someone associated with the Horse to do so. You may ask the testing personnel any questions you have, or ask them to explain the procedures you observe. Note: Testing personnel are required to wear gloves. Please report any instance where gloves are not used in the collection of a sample.

What if my Horse needs to go into another class or must remain at the ring for further performance in a class or to jog/be present for awards? What if the Horse is done showing and needs to be untacked and cooled out?

If you discuss these needs with the testing personnel, they will do their job so as not to interrupt the showing schedule or Horse's normal care, provided the collection of the samples is not unnecessarily delayed.

What protects the samples from having something put into them after collection or from being opened after they are collected?

Only new sample collection equipment is used, meaning blood tubes, needles, and urine sample containers. Also, all equipment and samples are kept either in the possession of the testing personnel, or under lock and key. Each sample is sealed with evidence tape, and placed in a plastic security bag. This is done while you watch. They are then locked up and kept secure. Any tampering of the sample would be evident if a seal or security bag were not intact.

What prevents a drug from getting into the urine container when the lid is off?

The lid is screwed onto the container tightly as soon as the sample is collected. If something accidentally touches the inside of the lid or container, for example, dirt or wood shavings, that container will not be used. The technician will replace the container with a new one before the sample is collected.

What is furosemide (Lasix®) used for?

Furosemide is a diuretic and is helpful in obtaining a urine sample. It is given by injection after the blood sample has been drawn and usually will provide a urine sample in 15-20 minutes. The dose given is 1/5 of the normal therapeutic dose given to race Horses. The use of furosemide is voluntary and is offered to expedite the collection of urine samples for the convenience of the exhibitor/trainer.

What prevents my Horse's samples from being mixed up with another Horse's samples?

As soon as each sample is collected, it is sealed and labeled with a unique number that is assigned only to your Horse's samples, and which remains attached to those samples from that time on.

If they ask to test my Horse, how can I be sure they are from USEF?

Each testing veterinarian has USEF documents specifying the competition to be tested, and a photo ID matching the documents, which they will present to you at your request.

Who selects the Horses for testing and who tests them?

The testing veterinarian selects the Horse. Testing veterinarians are representatives of the USEF and will not be working for any clients at the same competition. USEF appoints its veterinarians to attend specific shows and events, and they are accompanied by a team of several technicians who collect samples.

Why is a particular Horse selected?

USEF uses a multi-prong approach to select Horses for testing including random selection, selection based on placing, and intelligence-based selection.

Where are the samples collected?

Most often, at the Horse's own stall. Sometimes, a sample collection or "testing" stall is used.

What kinds of samples are collected and how much?

The testing veterinarian will collect a blood sample from each Horse, and the technician will attempt to collect a urine sample. Several tubes of blood are taken, some are labeled A, and some are labeled B. The technician will collect as much urine as the Horse will provide. The urine sample will be divided into two containers, as well, labeled A and B. Some drugs are measured or detected only in blood, and others are found only in urine. Some drugs are found in both. In some instances, the testing team may collect hair or other biological material from the Horse.

What is the exhibitor, trainer, or owner responsible for?

Please be courteous and make your Horse available promptly. You will be asked to provide accurate information to testing personnel and have an English speaking adult available to provide information about the Horse, the exhibitor, and the trainer. Please make sure you have an individual capable of safely holding the Horse for blood sample collection. Also, have an adult available to sign as a witness to the collection and sealing of all samples.

What about FEI competitions?

FEI competition testing is conducted in accordance with FEI regulations.

What happens to the samples after the competition or event?

They are shipped to the Federation's approved laboratory as soon as possible for testing. Upon arrival, each sample is inspected carefully and logged in.

The integrity of each sample and its identity is verified. The samples labeled A are tested, and the samples labeled B are stored securely.

Who is responsible in the event of an alleged violation of the rules?

The person who signs the entry form as the trainer of record will be responsible; however, additional persons responsible may be identified who have made a relevant decision about the Horse.

Do the chemists know the name of the Horse, owner, and trainer for each sample?

No, they only know the unique number assigned to the sample, the gender of the Horse, the date it was collected, and the name of the competition or event. The document that identifies the Horse, owner, and trainer is kept at the Equine Drugs and Medication Program's office in Ohio.

What kinds of tests are performed on the sample?

A broad range of screening tests are conducted. If any drugs are found, state-of-the art confirmatory tests identify the chemical identity of the drug or medication. No finding of a prohibited substance is reported unless the test result is certain.

Is there a way I can find out the status of my Horses' test?

Yes, please go to the Federation website usef.org/compete/resources-forms/rules-regulations/drugs-medications/barcode-lookup approximately four to six weeks following the sample collection. Type in your Horse's Sample ID number. The sample will either be listed as "Cleared" or "Pending".

What happens if nothing prohibited is detected in the sample?

The sample will be listed as "Cleared" when the Sample ID is entered on the USEF website.

What happens if something is detected in the "A Sample"?

You will be notified in writing. The B sample may be available for confirmatory analysis, in the event the trainer or owner wants it tested.

How long do they have to decide whether to test "B Sample"?

The request must be made within 10 business days following notification of positive by the Federation.

How is the equine drug program funded?

It is paid for by the \$15 per entry drug testing fee with no additional cost to the competitor.

CHAPTER 4 DRUGS AND MEDICATIONS

For purposes of this Chapter, the following definitions apply:

Drug Testing Personnel. Includes (i) any licensed veterinarian appointed by the Federation to perform duties under this Chapter; and (ii) any technician appointed by a Federation-appointed licensed veterinarian to perform duties under this Chapter.

Sample. Unless otherwise specified herein, means any biological or other material, including any tissue, body fluid, excreta, hair, skin scraping or swab collected for the purposes of analysis under the Federation rules.

Horse. Includes a horse, pony, or mule.

GR401-408, Equine Drugs and Medications Provisions Applicable to All Breeds and/or Disciplines.

GR401 Determining the Equine Drugs and Medications Designation for Each Breed or Discipline

1. The Board of Directors shall designate every Breed, Discipline, and/or Group competing under Federation Rules as either a Prohibited Substance Group or a Therapeutic Substance Group, as outlined herein below.
2. At each Annual Meeting, each Division Committee shall determine by a majority vote and shall indicate to the Chief Administrator of the Equine Drugs and Medications Program its preference for its Breed or Discipline to be designated as (or to be part of) either a Prohibited Substance Group or a Therapeutic Substance Group. In any instance where more than one Division Committee is responsible for a Breed and/or Discipline Group, after each committee has determined its preference by a majority vote, unanimity between and/or among the Division Committees of the Group shall be required to invoke a recommendation to be designated a Prohibited Substance Group. Absent such concurrence, the joint recommendation of the Division Committees of the Group shall be construed as a recommendation in favor of designation as a Therapeutic Substance Group.
3. Each Division Committee shall have responsibility to recommend for its division.
4. At its meeting at the Federation's Annual Meeting, the Veterinary Committee shall take into consideration these recommendations and the written recommendations of the respective Affiliate Associations in this regard, and it shall enact the designation for each Breed, Discipline, and/or Group. The effective dates of these designations shall coincide with the effective dates of the newly published Rule Book.
5. These designations shall be reviewed by each Division Committee at the subsequent Rule Change Convention.
6. Every Horse competing at Federation competitions and/or events shall be subject to either the Prohibited Substance Provisions (GR409) or the Therapeutic Substance Provisions (GR410-412), depending upon its Breed's, Discipline's, and/or Group's designation, and it shall be required to compete in compliance therewith,

whether competing in unrated or rated classes and/or divisions.

- Any Horse that competes in more than one Breed, Discipline, and/or Group at a competition, one of which is a Prohibited Substance Group, shall be required to be in compliance with the Prohibited Substance Provisions at all times while competing in any and/or all classes and/or divisions at that competition.

GR402 Testing

- Horses competing at a Licensed Competition are subject to examination by a licensed veterinarian appointed by the Federation. Said appointed veterinarian may appoint a technician to perform certain duties under Chapter 4. The examination may include physical collection of Samples and/or any other test or procedure at the discretion of said veterinarian necessary to effectuate the purposes of Chapter 4. Said veterinarian may examine any or all Horses in a class or all classes in a competition or any Horses entered in any class, whether in competition or not, if on the competition grounds, or any Horse withdrawn by any exhibitor within 24 hours prior to a class for which it has been entered.
- Whether a Horse is in competition or not, refusal to submit the Horse for examination or to cooperate with the Drug Testing Personnel constitutes a violation and subjects the responsible person to penalties under GR406.
- Trainers who are not able to accompany Drug Testing Personnel and the Horse to the location where Sample collection is to take place, to act as witness to the collection and sealing of Samples, and to sign the drug collection documents in the appropriate places as witness, must appoint an agent to do so. The absence of such a witness shall constitute a waiver of any objection to the identification of the Horse tested and the manner of collection and sealing of the Samples.
- Upon the collection of a sufficient number of tubes of blood from the Horse, the tubes shall be divided into two groups. One group shall be labeled and identified as Blood Sample A and the other as Blood Sample B, and they shall be sealed accordingly. Upon the collection of a sufficient volume of urine from the Horse, a portion of the Sample shall be poured into a second urine sample container. One container shall be labeled and identified as Urine Sample A and the other as Urine Sample B, and they shall be sealed accordingly. Upon collection of a sufficient amount of any other Sample from the Horse, a portion of the Sample shall be placed into a second sample container. One container shall be labeled and identified as Sample A and the other as Sample B, and they shall be sealed accordingly. NOTE: There is no Sample B for swabs. These procedures shall be performed whether or not the trainer or their appointed witness is present as provided for in Section 3 above.
- In the event reasonable attempts at Sample collections from the Horse do not provide a sufficient quantity of Sample material to be divided, labeled, and identified as Samples A and B, as determined by Drug Testing Personnel, the Sample(s) obtained (if obtained) shall be labeled and identified as Sample(s) A only, and it shall be recorded in the records of the Equine Drugs and Medications Program that the corresponding Sample(s) B does (do) not exist, in

which event the obtained Sample(s) shall be subject to testing.

- A Sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a Sample may lead to a violation only if the Sample was retested within three (3) years from the Sample collection date. In order to constitute a violation under these rules, the substance detected in the retested Sample must (i) have been prohibited at the time of the Sample collection; and (ii) not a therapeutic substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at fei.org/fei/cleansport) in effect on the Sample collection date.
- In the event that the retested Sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned.

GR403 Cooperation

- Cooperation with Drug Testing Personnel includes:
 - Taking the Horse and Drug Testing Personnel immediately to the location selected by Drug Testing Personnel for testing the Horse and presenting it for testing.
 - Assisting Drug Testing Personnel in procuring Samples promptly, including but not limited to removing equipment from the Horse, leaving it quietly in the stall and avoiding any distractions to it. Schooling, lengthy cooling out, bandaging and other delays of this type shall be construed as noncooperation.
 - Polite attitude and actions toward Drug Testing Personnel.
- It is a violation for any individual to attempt to intimidate or interfere with Drug Testing Personnel.

GR404 Accountability of Trainers and Other Persons Responsible

- Trainers and other Persons Responsible, in the absence of substantial evidence to the contrary, are responsible and accountable under the penalty provisions of these rules. The trainer and other Persons Responsible are not relieved from such responsibility as a result of the lack or insufficiency of stable security. For purposes of this rule, substantial evidence means affirmative evidence of such a clear and definite nature as to establish that said trainer, or any employee or agent of the trainer, was, in fact, not responsible or accountable for the condition of the Horse.
- The Persons Responsible may include the individual who rides, vaults, or drives the Horse during a competition; any Owner; and/or Support Personnel.
- Support Personnel is defined to include but is not limited to grooms, handlers, longeurs, and veterinarians. Support Personnel may be regarded as additional Persons Responsible if they are present at the competition or have made a relevant decision about the Horse.
- A trainer is defined as any adult or adults who has or shares the responsibility for the care, training, custody, condition, or

performance of a Horse. Said person must sign the entry blank of any Licensed Competition whether said person be a trainer, owner, rider, agent and/or coach. Where a minor exhibitor has no trainer, then a parent, guardian or agent or representative thereof must sign the entry blank and assume responsibility as trainer. The name of the trainer must be designated as such on the entry blank. It is the responsibility of trainers as well as competition management to see that entry blanks contain all of the required information. The responsibilities of a trainer include, but are not limited to the following:

- a. for the condition of a Horse at a Licensed Competition (whether or not they have signed an entry blank),
- b. to guard each Horse at, and sufficiently prior to, a Licensed Competition such as to prevent the administration by anyone of, or its exposure to, any prohibited substance, and
- c. to know all of the provisions of this Chapter 4 (including any advisories or interpretations published in equestrian) and all other rules and regulations of the Federation and the penalty provisions of said rules.
- d. If any trainer is prevented from performing their duties, including responsibility for the condition of the Horses in their care, by illness or other cause, or is absent from any Licensed Competition where Horses under their care are entered and stabled, the trainer must immediately notify the competition secretary and, at the same time, a substitute must be appointed by the trainer and such substitute must place their name on the entry blank forthwith. Such substitution does not relieve the regular trainer of their responsibility and accountability under this rule; however, the substitute trainer is equally responsible and accountable for the condition of such Horses.
5. The trainer and owner acknowledge that the trainer represents the owner regarding Horses being trained or managed, entries, scratches for any reason and any act performed on any Horse under the care and custody of the trainer.
6. In the case of a Horse competing under the Therapeutic Substance Provisions, any trainer and/or Persons Responsible subject to these rules who actually administers, attempts to administer, instructs, aids, conspires with another to administer or employs anyone who administers or attempts to administer a prohibited substance to a Horse which might affect the performance of said Horse at a competition licensed by the Federation without complying with GR411, is subject to the penalties provided in GR406.
7. Any trainer and/or other Persons Responsible subject to these rules who administers, attempts to administer, instructs, aids, conspires with another to administer or employs anyone who administers or attempts to administer any substance to a Horse by injection or by any other route of administration, whether the substance is prohibited or permitted, in the competition ring of a competition licensed by the Federation during a scheduled class, is subject to the penalties provided in GR406.

GR405 Equine Drugs and Medications Testing in Connection with an Appeal Measurement

1. Each animal submitted for an appeal measurement is subject to this Chapter at the time of said measurement and/or concurrent examinations, and said animal must be in compliance therewith.
2. Each animal submitted for an appeal measurement must have Samples collected at the time of said measurement and/or concurrent examinations. No Sample is a Sample as required under Chapter 4 unless it is collected by and/or under the direct supervision of Drug Testing Personnel, who must be appointed by the Federation to collect Samples from the animal in question in connection with said measurement.
3. All Samples must be of sufficient volume and amount for drug testing purposes, as determined by the Federation. Said Sample collections shall be conducted in accordance with procedures which are the sole prerogative of the Drug Testing Personnel. As deemed necessary by the Federation testing veterinarian, the animal shall be administered furosemide to cause it to produce a Urine Sample in a timely manner.
4. Every Sample collected in connection with an appeal measurement and all portions thereof are the sole property of the Federation. Said Samples and all portions thereof must remain in the sole custody of Drug Testing Personnel at all times during said measurement and/or concurrent examinations, and subsequently they must be submitted to the Federation's designated laboratory for testing in accordance with the instructions of the Federation.
5. The entire cost of Sample collections and testing conducted in connection with an appeal measurement, including the fees and expenses of Drug Testing Personnel, shipping costs for equipment and samples, laboratory charges, etc., as determined by the Federation, must be paid in full by the appellant within 30 days of the submission of an invoice, regardless of the outcome of said measurement, and regardless of the laboratory results. A deposit equal to the costs of sampling and testing, as estimated by the Federation, may be required prior to the measurement.
6. No appeal measurement is valid absent written affirmation of the CEO or their designee (i) confirming the receipt of negative drug testing results from the Federation's designated laboratory, and (ii) indicating that all Samples collected from the animal in question in connection with said measurement and/or concurrent examinations were found to contain no prohibited substance, said results having been issued to the Federation. Any instance involving a finding of prohibited substance shall additionally result in a violation of Chapter 4 for adjudication by the Hearing Committee in accordance with the Federation Bylaws.

GR406 Results, Confirmatory Analysis, and Retest

1. Samples labeled and identified as Samples A shall be subjected to chemical analysis by the Federation's designated laboratory. Samples labeled and identified as Samples B shall be stored securely, unopened, at the Federation's designated laboratory, to be used in the event of a confirmatory analysis, or in the event of a future analysis. Samples collected by the Federation are the property of the Federation, and the Federation is entitled to determine all matters regarding access to and the analysis and disposal of such Samples.
2. In the event the chemical analysis of Sample A is negative, i.e., no prohibited substance or any metabolite or analogue thereof is found to be present in the Sample, the corresponding Sample B may be frozen or stored, as appropriate, and maintained, at the Federation's designated laboratory, for possible future chemical analysis.
3. In the event the chemical analysis of Sample A is positive, i.e., a prohibited substance or any metabolite or analogue thereof is found to be present in the Sample, this shall be prima facie evidence that the prohibited substance was administered in some manner to said Horse, whether intentionally or unintentionally, or otherwise was caused to be present in the tissues, body fluids or excreta of the Horse at the competition, whether intentionally or unintentionally, such that the trainer(s) deemed responsible and accountable for its condition is (are) liable under the provisions of GR404.
4. In the event the chemical analysis of Sample A is positive, the Federation shall notify the Trainer, other Persons Responsible (if applicable), and the Owner of the Horse of their right to promptly request the analysis of the B Sample. They may waive analysis of the B Sample in which case they shall be deemed to accept the A Sample analytical results. If waived, the Federation may nonetheless elect to proceed with the B Sample analysis at its own expense. The Trainer, other Persons Responsible (if applicable), and the Owner of the Horse are deemed to have waived their right to a B Sample analysis if the Confirmatory Analysis Request Form is not received by the Federation within 10 calendar days from notification of the right to request such analysis. Upon receipt of the duly executed Confirmatory Analysis Request Form, the Federation shall make arrangements for analysis of the B Sample without undue delay. The party requesting the B Sample analysis must pay the costs associated therewith in advance, but if the B Sample analysis does not substantially confirm the A Sample analysis, such costs will be reimbursed by the Federation. If such costs required to be paid in advance are not paid to the Federation within five business days following the issuance of the invoice, the right to have the B Sample analysis performed will be deemed waived.
5. The party requesting the confirmatory analysis may elect to have the B Sample analyzed at a different laboratory than the one which performed the A Sample analysis. If such election is made, the Federation will select the B Sample laboratory. The choice of laboratory used for the confirmatory analysis of the corresponding Sample B will be determined exclusively by the Federation from the Federation Equestre Internationale list of approved laboratories or a laboratory recognized by the agency appointed by the horseracing Integrity and Safety Authority as meeting their laboratory standards. The Federation will inform the requesting party which laboratory it selected to analyze the corresponding B Sample.
6. The party requesting the analysis of the B Sample may send a representative (witness) to be present for the opening and identification of the B Sample, if possible, unless the Federation determines that allowing such representative (witness) may present a threat to the integrity of the analysis process. Such person does not have any right to witness the analysis of the B Sample. If the appointed representative (witness) claims that they are not available on the scheduled date indicated by the Federation, the Federation will liaise with the testing laboratory and propose two alternative dates. If the appointed representative (witness) claims not to be available on the alternative dates proposed, the Federation will instruct the testing laboratory to proceed without the representative (witness) present.
7. In the event that the Federation's designated laboratory conducts both the analysis of the Sample A and the confirmatory analysis of the Sample B, both the results of the analysis of Sample A (and supporting data) and the results of the confirmatory analysis of the corresponding Sample B, if any (and supporting data, if any), shall be admissible as evidence in any hearing or proceeding pertaining to this matter.
8. In the event the corresponding Sample B does not exist, or is of insufficient volume to permit a confirmatory analysis, and there exists a remaining aliquot of Sample A which is of sufficient volume to permit a retest, as determined by the Federation, the party who requests the retest of Sample A must make the request in writing to the Federation and it must be received within 7 days of the determination that the corresponding Sample B does not exist or is of insufficient volume to permit a confirmatory analysis. The party requesting the re-test must pay the costs associated therewith in advance, but if the re-test does not substantially confirm the A Sample analysis, such costs will be reimbursed by the Federation. If such costs required to be paid in advance are not paid to the Federation within five business days following the issuance of the invoice, the right to have the re-test performed will be deemed waived.
9. Any requested re-test of the remaining aliquot of Sample A, provided it is of sufficient volume to permit a retest, shall be performed by the Federation's designated laboratory.
10. After chemical analysis of the B Sample, or in the absence of the B Sample the re-test of the A Sample, if the laboratory's confirmatory analysis:
 - a. Does not substantially confirm the Federation's designated laboratory's findings, then any allegations that the substance in question was present at the time that the Samples were collected shall be dismissed; or
 - b. Substantially confirms the Federation's designated laboratory's findings, the finding shall be considered conclusive.

11. In the case of a Horse competing under the Therapeutic Substance Provisions, if the chemical analysis of the Sample taken from such Horse indicates the presence of a prohibited substance or any metabolite or analogue thereof and all the requirements of GR411 have been fully complied with, the information contained in said Equine Drugs and Medications Report Form and any other relevant evidence will be considered by the Federation in determining whether a rule violation was committed by the Trainer or other Persons Responsible or accountable for the condition of the Horse under the provisions of this rule.
12. No trainer, responsible or accountable for the condition of said Horse, will be suspended, or a Horse barred from competition, until after an administrative penalty has been assessed or after the conclusion of a hearing and a written ruling thereon has been made.
13. The owner or owners of a Horse found to contain a prohibited substance or any metabolite or analogue thereof may be required to forfeit all prize money, sweepstakes, added money and any trophies, ribbons and "points" won at said competition by said Horse and the same will be redistributed accordingly. The owner must pay a fee to said competition. Points accumulated toward Horse of the Year Awards prior to said competition may be nullified and redistributed at the discretion of the Hearing Committee. If, prior to or at a hearing, the Federation as the charging party, determines that one or more persons, not previously charged as a trainer should also be charged as a trainer, then, upon application by the Federation, the Hearing Committee may, in its discretion, continue or adjourn the hearing, in whole or in part, to permit a new or amended Disciplinary Action Complaint to be issued (unless the person(s) to be charged waive notice).
14. A trainer or other Persons Responsible of a Horse found to contain such prohibited substance or any metabolite or analogue thereof is subject to whatever penalty is assessed in accordance with the Federation Bylaws, rules, and published penalty guidelines.
15. If the Hearing Committee determines that any violation or attempted violation of this Rule was willful and/or intentional, there shall not be any limit to the period of a suspension, and the Hearing Committee may impose other and significantly greater penalties than it would have in the absence of such a determination.
16. A Sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a Sample may lead to a violation only if the Sample was retested within three (3) years from the Sample collection date. In order to constitute a violation under these rules, the substance detected in the retested Sample must (i) have been prohibited at the time of Sample collection; and (ii) not a therapeutic substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at <http://www.fei.org/fei/cleansport>) in effect on the Sample collection date.
17. In the event that the retested Sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned.

GR407 Management Procedures

1. To provide funds for research, inspection and enforcement of rules regarding use of medications and drugs, each Licensed Competition, except where prohibited by law, must assess the exhibitors a fee for each Horse entered in the competition. Participants in the following classes or competitions are exempted from payment:
 - a. leadline
 - b. exhibitions
 - c. games and races,
 - d. classes for 4-H members,
 - e. Recognized Academy classes at Dressage competitions.
 - f. Opportunity classes
 - g. Classes at Regular or Local Competitions restricted to breeds or disciplines whose rules are not included in the USEF rulebook.
 - h. Lite Competitions
 - i. However, these classes or competitions are not exempt from the Drugs and Medications Chapter itself. Within 10 days after a competition, competition management must forward to the Federation a sum representing the above fee times the number of Horses entered in the nonexempt classes of the competition plus the number of Horses scratched where the fee is not refunded, such sum to be held by the Federation in a separate fund for use to accomplish the purpose set forth above.
2. It is a violation for a Licensee to assess and/or collect a drug enforcement fee in excess of or in addition to that specified and required by GR407.1 of these rules, unless said assessment is approved in writing by the Federation in advance, and then only under the terms and conditions set forth.
3. It is a violation for a Licensee to withhold from the Federation any or all of the drug fees collected in accordance with GR407.1, for any purpose, including to defray the expenses incurred providing stalls, passes, and other items to Drug Testing Personnel, as required by GR407.4 and .5.
4. Each Licensed Competition shall, at its own cost and expense, set aside and make available to Drug Testing Personnel upon request suitable facilities conveniently located for the veterinarian appointed by Drug Testing Personnel to collect Samples. Suitable facilities means one or more stalls if available, as requested, that are well lit, clean, dry, freshly bedded, and having a door or gate that can be secured.
5. Each Licensed Competition, upon request, must furnish the veterinarian appointed by the Federation by mail forthwith, with the requested number of official passes and parking passes for Drug Testing Personnel to have immediate and free access to all areas at said Licensed Competition.
6. Competition management must cooperate with and exhibit polite attitude and actions toward Drug Testing Personnel.

GR408 Interpretations of the Federation Equine Drugs and Medications Chapter and its Application to Particular Substances

Any questions regarding the interpretation of this Chapter, including the application of this Chapter to particular substances, should be directed to the office of the Federation Equine Drugs and Medications Program, (800) 633-2472. Trainers and/or owners who seek advice concerning the interpretation and application of this rule should not rely solely upon interpretations or advice by private or competition veterinarians, competition officials, competition personnel, or other persons, but should also obtain verification of any such interpretations or advice from the Federation Equine Drugs and Medications Program office. Any trainer or owner who is uncertain about whether this rule applies in any given situation would be well advised to withdraw the affected Horse from competition until such time as the Federation Equine Drugs and Medications Program office has been consulted.

GR409 Equine Drugs and Medications, Prohibited Substance Provisions

1. This paragraph applies only to FEI Banned Substances and Methods.

For all Federation Equestre Internationale (FEI) recognized disciplines, Articles 2 (what constitutes a violation), 3 [proof of violations (except 3.1 and 3.2.3)], 4 (banned substances and methods), and 8.2 (principles of fair hearing) of the FEI Equine Anti-Doping rules govern. Those Articles are incorporated by reference as if fully set out herein and can be found at fei.org or the Drugs & Medications tab at usef.org. For purposes of this rule, the designation of “Person Responsible” in the incorporated provisions of the FEI Equine Anti-Doping rules shall refer to the individual(s) found to be the trainer of the Horse as defined by GR404.

2. No Horse competing in a Breed or Discipline designated as (or part of) a No Prohibited Substance Group is to be shown in any class at a competition licensed by the Federation if it has been administered in any manner or otherwise contained in its tissues, body fluids or excreta a prohibited substance as defined in the FEI Equine Anti-Doping and Controlled Medication Regulations, which can be found at www.fei.org.

3. EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, AND PRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM NO DOUBT CONTAIN ONE OR MORE PROHIBITED SUBSTANCES.

GR410 Equine Drugs and Medications, The Therapeutic Substance Provisions

1. No Horse competing in a Breed or Discipline designated as (or part of) a Therapeutic Substance Group is to be shown in any class at a competition licensed by the Federation (see also GR402.1, last sentence) if it has been administered in any manner or otherwise contains in its tissues, body fluids or excreta a prohibited substance except as provided in GR411. Any Horse that competes in more

than one Breed, Discipline, and/or Group at a competition, one of which is a Prohibited Substance Group, shall be required to be in compliance with the Prohibited Substance Provisions at all times while competing in any and/or all classes and/or divisions at that competition. For purposes of this rule, a prohibited substance is:

- a. Any stimulant, depressant, tranquilizer, local anesthetic, analgesic, psychotropic (mood and/or behavior altering) substance, or drug which might affect the performance of a Horse (stimulants and/or depressants are defined as substances which stimulate or depress the cardiovascular, respiratory or central nervous systems), or any metabolite and/or analogue of any such substance or drug, except as expressly permitted by this rule.
- b. Any corticosteroid present in the plasma of the Horse other than dexamethasone (see GR410.5b).
- c. Any nonsteroidal anti-inflammatory drug in excess of one present in the plasma or urine of the Horse (GR411 does not apply); exception: salicylic acid.
- d. Any substance (or metabolite and/or analogue thereof) permitted by this rule in excess of the maximum limit or other restrictions prescribed herein.
- e. Any substance (or metabolite and/or analogue thereof), regardless of how harmless or innocuous it might be, which might interfere with the detection of any of the substances defined in (a), (b), (c) or (f) or quantification of substances permitted by this rule.
- f. Any anabolic steroid (GR411 below does not apply).

2. EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, AND PRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM MAY CONTAIN A PROHIBITED SUBSTANCE.

3. The full use of modern therapeutic measures for the improvement and protection of the health of the Horse is permitted unless:

- a. The substance administered is a stimulant, depressant, tranquilizer, local anesthetic, analgesic, drug or drug metabolite which might affect the performance of a Horse or might interfere with the detection of prohibited substances or quantification of permitted substances; or
- b. More than one nonsteroidal anti-inflammatory drug is present in the plasma or urine of the Horse (GR411 does not apply); exception: salicylic acid; or
- c. The presence of such substance in the blood or urine sample exceeds the maximum limit or other restrictions prescribed herein below.

4. Restrictions concerning the nonsteroidal anti-inflammatory drugs are as follows:

- a. The maximum permitted plasma concentration of diclofenac is 0.005 micrograms per milliliter.

- b. The maximum permitted plasma concentration of phenylbutazone is 15.0 micrograms per milliliter.
 - c. The maximum permitted plasma concentration of flunixin is 1.0 micrograms per milliliter.
 - d. The maximum permitted plasma concentration of ketoprofen is 40.0 nanograms per milliliter.
 - e. The maximum permitted plasma concentration of meclofenamic acid is 2.5 micrograms per milliliter.
 - f. The maximum permitted plasma concentration of naproxen is 40.0 micrograms per milliliter.
 - g. The maximum permitted plasma concentration of firocoxib is 0.240 micrograms per milliliter.
 - h. Not more than one of the substances listed in (a) through (g) are permitted to be present in the same plasma or urine sample (GR411 does not apply).
 - i. Any nonsteroidal anti-inflammatory drug not listed in (a) through (g) above is prohibited from being present in the plasma or urine sample (GR411 does not apply); exception: salicylic acid.
 - j. Any nonsteroidal anti-inflammatory drug that becomes approved for use in Horses can be added to the list of those permitted, after the completion, review and approval of the needed research.
5. Restrictions concerning other therapeutic substances are as follows:
- a. The maximum permissible plasma concentration of methocarbamol is 0.5 micrograms per milliliter.
 - b. The maximum permitted plasma concentration of dexamethasone is 0.5 nanograms per milliliter.
6. Thresholds for substances of possible dietary origin are as follows:
- a. The maximum permissible urine concentration of theobromine is 2.0 micrograms per milliliter.

GR411 Conditions For Therapeutic Administrations of Prohibited Substances

1. A Horse exhibiting at a Licensed Competition pursuant to the Therapeutic Substance Provisions that receives any medication which contains a prohibited substance is not eligible for competition unless all of the following requirements have been met and the facts are furnished in writing on a timely-submitted official Equine Drugs and Medications Report Form online. A form is timely-submitted when the electronic form is submitted following administration and before the Horse competes (See (i) addressing the use of paper forms):
- a. The medication must be therapeutic and necessary for the diagnosis or treatment of an existing illness or injury. Administration of a prohibited substance for non-therapeutic or optional purposes (such as, by way of example only, shipping, clipping, training, turning out, routine floating or cleaning of teeth, nondiagnostic nerve blocking, uncasting, mane pulling or non-emergency shoeing) is not considered to be therapeutic. Any trainer who is uncertain about whether a particular purpose is considered to be therapeutic would be well advised to consult the Federation Equine Drugs and Medications Program office.

- b. The Horse must be withdrawn from competition for a period of not less than 24 hours after the medication is administered.
- c. The medication must be administered by a licensed veterinarian, or, if a veterinarian is unavailable, only by the trainer pursuant to the advice and direction of a veterinarian.
- d. Identification of medication—the amount, strength and mode of administration.
- e. Date and time of administration.
- f. Identification of Horse, its name, age, sex, color and entry number.
- g. Diagnosis and reason for administration.
- h. Statement signed by person administering medication.
- i. Equine Drugs and Medications Report Form must be filed following administration and prior to the Horse competing. If an online form cannot be submitted due to lack of internet or phone service, a paper form may be submitted. This option may only be used when submitting the online form is impossible.
- j. The Steward, Technical Delegate, or Designated Competition Office Representative must sign and record the time of receipt on the paper Equine Drugs and Medications Report Forms. The form must be filed with the Steward/Technical Delegate or Designated Competition Office Representative within one hour after administration. If administration occurred outside of competition hours, the form must be filed within one hour after the Steward/Technical Delegate or Designated Competition Office Representative returns to duty if administration took place at a time other than during competition hours. All required information must be included when filing a report. Failure to satisfy and follow all the requirements of this Rule and to supply all of the information required by such Equine Drugs and Medications Report Form is a violation of the rules. The Steward/Technical Delegate must report any known violations of this Rule to the Federation for such further action as may be deemed appropriate.
- k. At selection trials for World Championships, and/or Olympic and/or Pan American Games, the requirement of subsection (b) above, that the Horse must be withdrawn from competition for a period of not less than 24 hours after the medication is administered will not apply, provided that:

- 1. the competition is conducted pursuant to the written selection procedures as approved by the Federation Board of Directors;
- 2. the written selection procedures specifically allow for therapeutic administrations of medications by a USEF-appointed veterinary panel within 24 hours preceding competition, and the written selection procedures are in no case less stringent in this regard than the FEI Veterinary Regulations (Articles 1006.7 and 1006.8) and guidelines pursuant thereto;
- 3. all requirements of the written selection procedures regarding therapeutic administrations of medications have been met;
- 4. all requirements of this Rule have been met except subsection GR411.1(b); and all persons competing in the competition are eligible and competing for selection.

2. Where all the requirements of GR411 have been fully complied with, the information contained in said Equine Drugs and Medications

Report Form and any other relevant evidence will be considered by the Federation in determining whether a rule violation was committed by any other Persons Responsible or accountable for the condition of the Horse under the provisions of this rule.

3. Flunixin, in addition to one other substance listed in GR410 (a) through (g), may be found in the same plasma and/or urine sample of a Horse under the following conditions and for the treatment of colic or an ophthalmic emergency only: (i) must comply with GR411.1; (ii) the flunixin must have been administered by a veterinarian; (iii) the required Medication Report Form must be signed by the administering veterinarian, submitted appropriately, and in accordance with GR411; and (iv) the Horse must be withdrawn from competition for 24 hours following the administration.

GR412 Administrative Penalties

Repealed

GR413 Human Drug Testing

1. In accordance with the rules of the FEI and of the World Anti-Doping Agency (WADA), any Federation member shall comply with in-competition, no advance notice (NAN), and other out-of-competition drug testing conducted by the FEI, WADA, US Anti-Doping Agency (USADA) or by a WADA-authorized organization or USADA-authorized organization at any time without advanced notice. Failure to cooperate with such in-competition, NAN or other out-of-competition drug testing shall be a violation of Federation rules.
2. In conjunction with the above-described NAN or other out-of-competition drug testing, the Federation is required to submit the names, current addresses, telephone numbers, training times and training and competition locations for individuals and teams as requested by the FEI, WADA, or USADA to enable FEI, WADA, or USADA to conduct NAN or other out-of-competition drug testing. Notwithstanding the foregoing, compliance with anti-doping regulations rests with the individual subject to testing.
3. A finding of violation of human drug rules by USADA or WADA shall be deemed a violation of Federation rules, and the reciprocity provisions of the Federation's Bylaws shall be applied.

GR 414 Prohibited Practices

1. No injectable substances may be administered to any Horse within 12 hours prior to competing, with the following three exceptions subject to paragraph 2 below:
 - a. Therapeutic fluids, which amount must consist of a minimum of 1L of polyionic fluids per 100lb of body weight; and which must be used in accordance with the manufacturer's recommendations and guidelines. The fluids must not be supplemented with concentrated electrolytes, such as magnesium.
 - b. Antibiotics. Procaine penicillin G is prohibited under this exception.
 - c. Dexamethasone. This is permitted only for the treatment of acute urticaria (hives). The dose must not exceed 0.5 mg per 100 lb (5.0 mg for 1000 lb Horse) if administered more than 6 hours and less

than 12 hours prior to entering the competition ring, and must not exceed 1.0 mg per 100 lb (10.0 mg for 1000lb Horse) within any 24 hour period.

2. The above exceptions are permitted only when (i) the substance is administered by a licensed veterinarian and no less than 6 hours prior to competing; and (ii) the "Trainer" as defined under General Rule 404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form following administration and prior to the Horse competing.
3. No Horse may be injected with any substance, prohibited or permitted, into an intra-synovial space (joint, tendon sheath, or bursa) within the 4 days preceding competition. No Horse less than two years of age may be treated with intrasynovial injections within the 30 days preceding competition.
4. Only a licensed veterinarian may administer Shockwave Therapy on competition grounds. No Shockwave Therapy is permitted within the 12 hours prior to competing.
 - a. If sedation is required for Shockwave Therapy, only sedation performed by a licensed veterinarian and administered at the same time as the Shockwave Therapy will be considered therapeutic and GR411 will apply. No sedation associated with Shockwave Therapy will be considered therapeutic if administered within 24 hours prior to competition.
 - b. Shockwave Therapy administered within the three days preceding competition must be limited to application to the back, neck, and dorsal pelvis areas. This exception is permitted only when the "Trainer" as defined under GR404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form after administration and prior to the Horse competing. If an online form cannot be submitted due to lack of internet or phone service, a paper form may be submitted. The form must be filed with the Steward/Technical Delegate or competition office representative within one hour after the administration of Shockwave Therapy. If administration occurred outside of competition hours, the form must be filed within one hour after the Steward/Technical Delegate or competition office representative returns to duty if the administration occurs at a time outside competition hours. The Steward/Technical Delegate or competition office representative shall sign and record the time of receipt on the Equine Drugs and Medications Report Form.
5. No kinesiotape or self-adhesive patches may be used on any Horse while competing. Kinesiotape and self-adhesive patches are permitted exclusively while the Horse is unmounted in the stabling area. Nasal strips are permitted unless prohibited by specific division rules.
6. It is a prohibited practice to administer bisphosphonates, except in Horses four years of age or older and when using bisphosphonates that are FDA approved for use in Horses. GR411 must be followed.
7. It is a prohibited practice to compete in Federation competitions with a tracheotomy/tracheostomy (i.e. surgical opening through the skin into the trachea).

8. It is a prohibited practice to use and/or possess any of the following substances on competition grounds:

- a. Injectable ACTH
- b. Injectable Adenosine
- c. Injectable Formaldehyde
- d. Injectable Magnesium Sulfate
- e. Injectable Melatonin
- f. Injectable Oxytocin
- g. Injectable Pentobarbital, except by a veterinarian for the purpose of euthanasia
- h. Injectable Thiamine
- i. Injectable Tryptophan
- j. Liquid Nitrogen
- k. Any injectable prescription medication in any formulation without a manufacturer or compound pharmacy label that identifies all ingredients.

9. It is a prohibited practice to rectally administer any substance on the grounds of a Federation competition.

Understanding the USEF Equine Drugs and Medications Rule will help avoid inadvertent violations. All questions about the rule should be directed to the USEF Equine Drugs and Medications Program at

800.633.2472, medequestrian@usef.org

SIGN UP TODAY!

Become a FREE fan
of US Equestrian to
receive Horse health tips,
educational resources,
and helpful guides
and materials.

Fans of US Equestrian
get access to free
Learning Center
videos, Livestreams,
MemberPerks, and More!



usef.org/fan/Horsehealth

© All rights reserved. 2026 by United States Equestrian Federation®
Reproduction without permission is strictly prohibited.